VanEck非必需消费品TruSector主动型ETF TRUD 深 沪
等待开盘 03-26 09:30:00 美东时间
24.155
+0.305
+1.28%
华盛通- 最 高24.25
- 今 开24.25
- 成交量 2.30万股
- 最 低 24.07
- 昨 收 23.8502
- 总市值 1932.40万
- 52周最高 27.50
- 市盈率 静 --
- 换手率 2.88%
- 52周最低 23.28
- 委 比 3.35%
- 总股本 80.00万
- 历史最高 27.50
- 量 比 0.05
- 振 幅 0.75%
- 历史最低 23.28
- 每 手 1
- 风险率 0.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pyxis Oncology FY 2025 R&D expenses rose 25.45% to USD 74 million, net loss widened to USD 79.62 million
Pyxis Oncology FY 2025 R&D expenses rose 25.45% to USD 74 million, net loss widened to USD 79.62 million Pyxis published a press release providing a business update and reporting fourth quarter and full-year 2025 financial results. Full-year revenue fell 13.9% to USD 13.9 million, while R&D expense
03-23 19:07
Citius Oncology Announces Data From Phase 1 Clinical Study Of Direct T-Regulatory Cell Depletion Activity Of LYMPHIR Shows 24% Objective Response Rate, 48% Clinical Benefit Rate In Participants With Recurrent Or Refractory Gynecologic Cancers
Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced
03-10 20:49
VanEck Targets India Growth Surge With New ETF As Investors Reassess Emerging Markets Exposure
VanEck launched an active India ETF and a communications sector ETF, targeting emerging markets growth and reducing sector tracking distortions.
02-25 04:38
BRIEF-Lassonde Industries Announces CFO Succession Plan
BRIEF-Lassonde Industries Announces CFO Succession Plan Feb 19 (Reuters) - Lassonde Industries Inc LASa.TO : LASSONDE INDUSTRIES INC. ANNOUNCES CHIEF FINANCIAL OFFICER SUCCESSION PLAN LASSONDE INDUSTRIES INC - APPOINTS FRANCIS TRUDEAU AS EXECUTIVE VICE-PRESIDENT FINANCE LASSONDE INDUSTRIES INC: NOMI
02-20 07:00
BRIEF-Health Canada Approves Keytruda SC™, A Subcutaneous Formulation Of Pembrolizumab Across Multiple Cancer Indications
BRIEF-Health Canada Approves Keytruda SC™, A Subcutaneous Formulation Of Pembrolizumab Across Multiple Cancer Indications Feb 17 (Reuters) - HEALTH CANADA : HEALTH CANADA APPROVES KEYTRUDA SC™, A SUBCUTANEOUS FORMULATION OF PEMBROLIZUMAB ACROSS MULTIPLE CANCER INDICATIONS (( Reuters.Briefs@thomsonre
02-18 01:30
Merck's KEYTRUDA SC Receives Health Canada Approval
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA SC™ (pembrolizumab injection), a new subcutaneous formulation of
02-18 00:03
FDA Approves Merck's KEYTRUDA Regimen for Platinum-Resistant Ovarian Cancer
FDA Approves Merck's KEYTRUDA Regimen for Platinum-Resistant Ovarian Cancer The U.S. Food and Drug Administration (FDA) has approved Merck & Co. Inc.'s KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in combination with paclitaxel, with or without bevaciz
02-11 19:45
Immutep Achieves 50% Participant Enrollment Target In TACTI-004 Phase III Study Evaluating Eftilagimod Alfa In Combination With Merck's Anti-PD-1 Therapy
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has achieved 50% of the patient enrolment target in
02-06 21:04
Merck Q4 revenue misses estimates on lower Gardasil demand
Merck Q4 revenue misses estimates on lower Gardasil demand Overview Pharmaceutical firm's Q4 revenue grew 5% but missed analyst expectations Adjusted EPS for Q4 beat analyst expectations Company highlighted progress in pipeline and acquisitions Outlook Merck anticipates 2026 sales between $65.5 bln
02-03 19:39
Merck posts Q4 diluted EPS of USD 1.19, down 20%
Merck posts Q4 diluted EPS of USD 1.19, down 20% Merck & Co. Inc. reported its financial results for the fourth quarter (Q4) and full year (FY) 2025. For Q4 2025, net income attributable to shareholders was USD 2.96 billion, with diluted earnings per share (EPS) of USD 1.19. For the full year 2025,
02-03 19:31
